Please use this identifier to cite or link to this item:
http://hdl.handle.net/2445/188964
Title: | Impaired antigen-specific B-cell responses after Influenza vaccination in kidney transplant recipients receiving co-stimulation blockade with Belatacept |
Author: | Pernin, Vincent Meneghini, Maria Torija, Alba Jouve, Thomas Del Bello, Arnaud Sanz Muñoz, Iván Eiros, Jose Maria Donadeu, Laura Polo, Carol Morandeira, Francisco Navarro, Sergio Masuet Aumatell, Cristina Favà Buch, Alexandre Lequintrec, Moglie Kamar, Nassim Crespo, Elena Bestard Matamoros, Oriol |
Keywords: | Virus de la gripe Trasplantament renal Influenzavirus Kidney transplantation |
Issue Date: | 29-Jul-2022 |
Publisher: | Frontiers Media SA |
Abstract: | Emerging data suggest that costimulation blockade with belatacept effectively controls humoral alloimmune responses. However, whether this effect may be deleterious for protective anti-infectious immunity remains poorly understood. We performed a mechanistic exploratory study in 23 kidney transplant recipients receiving either the calcineurin-inhibitor tacrolimus (Tac, n=14) or belatacept (n=9) evaluating different cellular immune responses after influenza vaccination such as activated T follicular Helper (Tfh), plasmablasts and H1N1 hemagglutinin (HA)-specific memory B cells (HA(+)mBC) by flow-cytometry, and anti-influenza antibodies by hemagglutination inhibition test (HI), at baseline and days 10, 30 and 90 post-vaccination. The proportion of CD4+CD54RA-CXCR5+ Tfh was lower in belatacept than Tac patients at baseline (1.86%[1.25-3.03] vs 4.88%[2.40-8.27], p=0.01) and remained stable post-vaccination. At M3, HA(+)mBc were significantly higher in Tac-treated patients (0.56%[0.32-1.49] vs 0.27%[0.13-0.44], p=0.04) and correlated with activated Tfh numbers. When stratifying patients according to baseline HA(+)mBc frequencies, belatacept patients with low HA(+)mBC displayed significantly lower HA(+)mBc increases after vaccination than Tac patients (1.28[0.94-2.4] vs 2.54[1.73-5.70], p=0.04). Also, belatacept patients displayed significantly lower seroprotection rates against H1N1 at baseline than Tac-treated patients (44.4% vs 84.6%) as well as lower seroconversion rates at days 10, 30 and 90 after vaccination (50% vs 0%, 63.6% vs 0%, and 63.6% vs 0%, respectively). We show the efficacy of belatacept inhibiting T-dependent antigen-specific humoral immune responses, active immunization should be highly encouraged before starting belatacept therapy. |
Note: | Reproducció del document publicat a: https://doi.org/10.3389/fimmu.2022.918887 |
It is part of: | Frontiers in Immunology, 2022, vol. 13 |
URI: | http://hdl.handle.net/2445/188964 |
Related resource: | https://doi.org/10.3389/fimmu.2022.918887 |
ISSN: | 1664-3224 |
Appears in Collections: | Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL)) |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
fimmu-13-918887.pdf | 5.55 MB | Adobe PDF | View/Open |
This item is licensed under a
Creative Commons License